To read a PDF of this press release including balance sheets, please click here.

Conference Call scheduled for today, March 25th at 4:30 p.m. ET

AUSTIN, Texas — March 25, 2021 — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2020.

“In a year dominated by the pandemic, we delivered strong stock price appreciation, growth in revenue and test volume, and financial stability. In addition, we strengthened our team and board of directors. We are starting 2021 by announcing an accelerated product launch of OVASight, a new strategic partnership and increases in our sales footprint.“ stated Valerie Palmieri, President and CEO.

Recent Corporate Highlights 

Acceleration of Launch Date of OVASight to Fourth Quarter 2021

Aspira announced the acceleration of the target launch date of  OVASight to the fourth quarter of 2021 with full national availability in 2022. This test allows physicians to classify suspected benign masses as low or high risk for malignancy to help guide clinical management. The test is specifically designed for a population with a low prevalence of disease, and we estimate it may reach approximately 1.2 million to 1.5 million additional women in the United States.

Strategic Research Collaboration to Develop a Combined Technology Product-
Development of Highly Sensitive and Specific Proteomic and Transcriptomics Early Detection Test For Women With High-Risk Of Ovarian Cancer

Aspira announced it has entered into an agreement with Dana Farber Cancer Institute (DFCI), Brigham and Women’s Hospital, and Medical University Lodz to evaluate their jointly-developed novel microRNA (miRNA) technology in combination with current Aspira technologies, for the development of a highly sensitive and specific early detection test for women with high-risk of ovarian cancer.

New York Medicaid Coverage

We announced coverage by New York State Medicaid – one of the larger Medicaid populations in the U.S., covering 33% of the population in the state. This is a significant add to serve this underserved population in New York State, and this will bring our total covered lives to approximately 179M or 54% of the U.S. population as of April 1, 2021.


On February 8, 2021, the Company completed an offering of Aspira common stock resulting in net proceeds of approximately $48.4 million, including full exercise of the underwiters option to purchase additional shares and after giving effect to underwriting discounts but before expenses.

Board Update

Aspira announced the appointment of Nicole Sandford to its board of directors. The board is now 71% female.

Financial Highlights

Quarter over Quarter Results – Fourth Quarter 2020 versus Fourth Quarter 2019:

Year over Year Results – Full Year of 2020 versus Full Year 2019:

Fourth Quarter Highlights:

Conference Call and Webcast

Aspira will host a call today at 4:30 p.m. Eastern Time to discuss results followed by a question and answer period.

Thursday March 25th @ 4:30pmET

877-407-4018 ß Investors Dial

201-689-8471 ß Int’l Investors Dial

13717832 ß Conference ID